Quiet Friday should allow greater attention on small caps

Delayed numbers had been expected by car dealer Lookers but this was due to a mistake on its website

Verona Pharma -

Friday will be a quiet day, according to the City diary, perhaps allowing greater attention on some of the London market's smaller fry.

Among the macro data, the US will be the main focus, with industrial production and retail sales figures as various of the states order businesses to close their doors again to contain the spread of the coronavirus.

Among the small smattering of results, there are interims expected from AIM-listed biotech Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) and Westminster Group PLC (LON:WSG), the security and technology group.

Verona last month raised a whopping US$200mln from new and existing investors to fund the clinical development of its breakthrough treatment for chronic obstructive pulmonary disease (COPD).

Back in May, the company was given the regulatory green light for two phase III studies of the nebulised formulation of its COPD drug, following a meeting with the US Food & Drug Administration where guidance was given on dosing, primary and secondary endpoints, patient population and study design.

Over at Westminster, the company said in a trading update last month that revenues in the first half of the year had jumped by around a quarter in spite of the coronavirus pandemic.

It revealed that half-year revenues were up 24% with the company saying it made a profit, the precise quantum of which will be revealed this week.

Significant announcements expected on Friday, August 14:

Interims: Westminster Group PLC (LON:WSG), Verona Pharma PLC (LON:VRP), Yew Grove REIT PLC (LON:YEW),

AGMs: Adamas Finance Asia Limited (LON:ADAM); Baker Steel Resources Trust Ltd (LON:BSRT), NewRiver REIT plc (LON: NRR)

Economic data: US retail sales, US industrial production

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


GinsGlobal Managing Director sees Healthcare and Healthcare innovation as...

HANetf and GinsGlobal Index Funds' Managing Director Anthony Ginsberg joined Steve Darling from Proactive to share details about the success of their Healthcare Innovations ETF. Ginsberg discusses how COVID-19 had made a direct impact on that fund, especially in the telemedicine...

2 days, 3 hours ago

2 min read